| Chronic Obstructive Airway Disease
Dalisrep vs Tudorza Pressair
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Daliresp vs Tudorza Pressair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTudorza Pressair has a higher rate of injection site reactions vs Daliresp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tudorza Pressair but not Daliresp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Daliresp
Tudorza Pressair
At A Glance
Oral
Daily
PDE4 inhibitor
Oral inhalation
Twice daily
Anticholinergic
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease Maintenance dose: 500 mcg once daily, with or without food; an optional titration of 250 mcg once daily for the first 4 weeks may reduce discontinuation rates, but 250 mcg is not the effective therapeutic dose.
Chronic Obstructive Airway Disease One oral inhalation of 400 mcg twice daily (morning and evening approximately 12 hours apart).
Contraindications
- Moderate to severe liver impairment (Child-Pugh B or C)
- Severe hypersensitivity to milk proteins
- Hypersensitivity to aclidinium bromide or any excipient
Adverse Reactions
Most common (>=2%) Diarrhea, weight decreased, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite
Serious Diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure
Postmarketing Hypersensitivity reactions (angioedema, urticaria, rash), gynecomastia
Most common (>=1%) Headache, nasopharyngitis, cough, diarrhea, sinusitis, rhinitis, toothache, fall, vomiting
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Anaphylaxis, angioedema, urticaria, rash, bronchospasm, itching, nausea, dysphonia, blurred vision, urinary retention, tachycardia, stomatitis
Pharmacology
Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4); inhibition of PDE4 leads to accumulation of intracellular cyclic AMP in lung tissue, which is thought to underlie its therapeutic action in COPD.
Aclidinium bromide is a long-acting antimuscarinic (anticholinergic) agent that inhibits M3 muscarinic receptors on airway smooth muscle, causing bronchodilation; the bronchodilatory effect is predominantly site-specific following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Daliresp
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Tudorza Pressair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Daliresp
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (7/8)
Tudorza Pressair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Daliresp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Tudorza Pressair
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Daliresp.
No savings programs available for Tudorza Pressair.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DalirespView full Daliresp profile
Tudorza PressairView full Tudorza Pressair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.